SCHEMBL1409752

SCHEMBL1409752

CC(C)(C)c1cc(N)n(-c2cccc(O)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRN P28799 1/20 0.46
SORT1 Q99523 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MAPK14 Q16539 9/20 0.44
MAPK11 Q15759 6/20 0.44
MAPK13 O15264 5/20 0.44
MAPK12 P53778 5/20 0.44
DDR2 Q16832 3/20 0.44
SRC P12931 2/20 0.42
HTR7 P34969 1/20 0.42
HTR2B P41595 1/20 0.42
CYP1A2 P05177 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ABL1 P00519 2/20 0.41
MAPK9 P45984 1/20 0.41
ABL2 P42684 1/20 0.41
MAPK8 P45983 1/20 0.41
KIT P10721 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31265737 1.00 GRN (0.46) GRNSORT1ALDH1A1MAPK14MAPK11
SCHEMBL4079578 0.86 MAPK13 (0.44) ALDH1A1MAPK14MAPK11MAPK13MAPK12
SCHEMBL4076195 0.86 SMN1; SMN2 (0.44) GRNSORT1ALDH1A1MAPK14MAPK11
SCHEMBL16279476 0.85 ALDH1A1 (0.40) ALDH1A1MAPK14MAPK11MAPK13MAPK12
SCHEMBL1013681 0.83 ALDH1A1 (0.67) GRNSORT1ALDH1A1MAPK14MAPK11
SCHEMBL1283896 0.83 CDK8 (0.47) GRNSORT1ALDH1A1MAPK14MAPK11
SCHEMBL4080963 0.83 SMN1; SMN2 (0.41) ALDH1A1MAPK14MAPK11MAPK13MAPK12
SCHEMBL1264553 0.82 CYP1A2 (0.61) GRNSORT1ALDH1A1MAPK14MAPK11
SCHEMBL1012342 0.82 MAPK14 (0.50) GRNSORT1ALDH1A1MAPK14MAPK11
SCHEMBL2083103 0.82 ALDH1A1 (0.45) GRNSORT1ALDH1A1MAPK14MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788345-B1 DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARM SPA (IT) 2020-06-10 EP disclosed
EP-2788345-B1 DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARM SPA (IT) 2020-06-10 EP disclosed
US-9527846-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
US-9527846-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
US-9527846-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
EP-2788349-B1 KINASE INHIBITORS CHIESI FARMA SPA (IT) 2016-10-26 EP disclosed
EP-2788349-B1 KINASE INHIBITORS CHIESI FARMA SPA (IT) 2016-10-26 EP disclosed
EP-2788348-B1 KINASE INHIBITORS CHIESI FARMA SPA (IT) 2016-10-19 EP disclosed
US-9458154-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-04 US disclosed
US-9458154-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-04 US disclosed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 WO disclosed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 WO disclosed
CN-101010315-A Substituted pyrazolyl urea derivatives useful in the treatment of cancer BAYER PHARMACEUTICALS CORP (US) 2007-08-01 CN disclosed
WO-2007064872-A2 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE LLC (US) 2007-06-07 WO disclosed
WO-2007059202-A2 PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE AG (DE) 2007-05-24 WO disclosed
WO-2007059202-A2 PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE AG (DE) 2007-05-24 WO disclosed
EP-1751139-A2 SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Bayer Pharmaceuticals Corporation (US) 2007-02-14 EP disclosed
WO-2006081034-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-08-03 WO disclosed
US-20060035922-A1 Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors PFIZER INC. 2006-02-16 US disclosed
WO-2005110994-A2 SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER BAYER PHARMACEUTICALS CORPORATION (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035922-A1 Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors MAPK1, MAPKAPK5, MAPKAPK3 GRN 1727/4885SORT1 3609/4885ALDH1A1 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.